7Baggers

Ocugen, Inc
(NASDAQ:OCGN) 

OCGN stock logo

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherit...

Founded: 2013
Full Time Employees: 16
CEO / Co-Founder: Shankar Musunuri 
Sector: Healthcare
Industry: Biotechnology
BiotechnologyGene Therapy
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 
                                                  
      collaborative arrangement revenue
    		1,533,000 -193,000 1,752,000 1,373,000 1,481,000 764,000 1,136,000 1,141,000 1,014,000                                      
      total revenue
    		1,533,000 -193,000 1,752,000 1,373,000 1,481,000 764,000 1,136,000 1,141,000 1,014,000                                      
      yoy
    		3.51% -125.26% 54.23% 20.33% 46.06%                                          
      qoq
    		-894.30% -111.02% 27.60% -7.29% 93.85% -32.75% -0.44% 12.52%                                       
      operating expenses
    		                                              
      research and development
    		11,255,000 10,669,000 11,149,000 8,402,000 9,529,000 8,290,000 8,108,000 8,902,000 6,826,000 9,504,000 6,342,000 14,169,000 9,558,000 17,213,000 15,622,000 9,007,000 7,915,000 7,102,000 6,281,000 18,853,000 2,872,000 1,593,718 1,477,382 1,629,869 1,652,318 1,746,992 1,305,461 446,000 1,583,000 3,327,000 4,563,000 4,458,000 3,286,000 3,366,000 3,488,000 4,208,000 4,504,000 5,317,000 4,880,000 5,794,000 5,586,000 5,773,000 5,848,000 5,858,000 5,764,000  
      general and administrative
    		8,117,000 6,133,000 8,228,000 6,766,000 6,453,000 6,314,000 6,280,000 7,688,000 6,404,000 5,155,000 9,082,000 9,564,000 8,193,000 6,937,000 7,497,000 10,558,000 10,119,000 7,470,000 4,508,000 6,757,000 4,185,000 2,213,652 1,704,598 1,779,016 2,276,784 2,532,250 1,408,350 2,614,000 2,929,000 2,145,000 2,426,000 2,826,000 2,807,000 2,667,000 2,225,000 2,166,000 2,326,000 2,389,000 1,768,000 2,161,000 2,212,000 2,231,000 2,191,000 1,735,000 2,109,000  
      total operating expenses
    		19,372,000 16,802,000 19,377,000 15,168,000 15,982,000 14,604,000 14,388,000 16,590,000 13,230,000 14,659,000 15,424,000 23,733,000 17,751,000 24,150,000 23,119,000 19,565,000 18,034,000 14,572,000 10,789,000 25,610,000 7,057,000 3,807,370 10,181,980 3,408,885 3,929,102 4,279,242 2,713,811 3,060,000 8,051,000 9,742,000 6,989,000 7,284,000 6,093,000 6,033,000 5,713,000 6,374,000 6,830,000 7,906,000 6,648,000 7,955,000 7,798,000 8,314,000 8,039,000 7,593,000 7,873,000  
      income from operations
    		-17,839,000 -16,995,000 -17,625,000 -13,795,000 -14,501,000 -13,840,000 -13,252,000 -15,449,000 -12,216,000 -8,623,000 -15,424,000 -23,733,000 -17,751,000 -24,150,000 -23,119,000 -19,565,000 -18,034,000 -14,572,000 -10,789,000 -25,610,000 -7,057,000 -3,807,370 -10,181,980 -3,366,265 -3,929,102   -3,060,000 -8,051,000 -9,742,000 -6,989,000 -7,284,000 -6,093,000 -6,033,000 -5,713,000 -6,374,000 -6,830,000 -7,906,000 -6,648,000 -7,955,000 -7,798,000 -8,314,000 -8,039,000 -7,593,000 -7,873,000  
      yoy
    		23.02% 22.80% 33.00% -10.71% 18.70% 60.50% -14.08% -34.90% -31.18% -64.29% -33.28% 21.30% -1.57% 65.73% 114.28% -23.60% 155.55% 282.73% 5.96% 660.78% 79.61%   10.01% -51.20%   -57.99% 32.14% 61.48% 22.34% 14.28% -10.79% -23.69% -14.06% -19.87% -12.41% -4.91% -17.30% 4.77% -0.95%      
      qoq
    		4.97% -3.57% 27.76% -4.87% 4.78% 4.44% -14.22% 26.47% 41.67% -44.09% -35.01% 33.70% -26.50% 4.46% 18.17% 8.49% 23.76% 35.06% -57.87% 262.90% 85.35% -62.61% 202.47% -14.32%    -61.99% -17.36% 39.39% -4.05% 19.55% 0.99% 5.60% -10.37% -6.68% -13.61% 18.92% -16.43% 2.01% -6.21% 3.42% 5.87% -3.56%   
      operating margin %
    		-1163.67% 8805.70% -1005.99% -1004.73% -979.14% -1811.52% -1166.55% -1353.99% -1204.73% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity%  
      interest income
    		132,000 144,000 207,000 -1,058,000 -914,000             3,750 5,000 10,000  471 42 433 119 107 136 7,000 48,000 75,000 19,000 32,000 37,000 20,000 39,000 40,000 35,000          
      interest expense
    		-1,320,000 -1,332,000 -1,314,000               -20,000 -19,000 -20,000 -20,000 -166,162 -291,909 -248,143 -14,749             -5,000 -20,000 -17,000 -19,000 -22,000 -23,000 -26,000 -62,000  
      other income
    		-150,000 477,000 -1,319,000 114,000 65,000 -40,000 282,000 169,000 292,000 -870,000 1,262,000 808,000 1,253,000 2,211,000 1,197,000 94,000 15,000 26,000 -4,000 -332,000  182,749   -87   92,000              -13,000 -16,000 -14,000 -29,000  
      total other income
    		-1,338,000 -711,000 -2,426,000               -9,000 -18,000 -342,000 -20,000 17,058 -291,867 -247,710 -14,717   -176,000 -1,364,000 8,924,000 17,774,000 3,507,000          -35,000 -39,000 -40,000 -91,000  
      net income
    		-19,177,000 -17,706,000 -20,051,000 -14,739,000 -15,350,000 -13,880,000 -12,970,000 -15,280,000 -11,924,000 -9,493,000 -14,162,000 -22,925,000 -16,498,000 -21,939,000 -21,922,000 -19,471,000      -3,790,312 -10,473,847 -3,613,975 -3,943,819 12,382,067 -22,773,281 -3,236,000 -9,415,000 -818,000 10,785,000 -3,777,000 -14,833,000 -6,796,000 -5,995,000 -6,542,000 -7,081,000 9,063,000 -9,315,000 -8,038,000 -7,918,000 -8,349,000 -8,078,000 -7,633,000 -7,964,000  
      yoy
    		24.93% 27.56% 54.60% -3.54% 28.73% 46.21% -8.42% -33.35% -27.72% -56.73% -35.40% 17.74%          -130.61% -54.01% 11.68% -58.11% -1613.70% -311.16% -14.32% -36.53% -87.96% -279.90% -42.27% 109.48% -174.99% -35.64% -18.61% -10.57% -208.55% 15.31% 5.31% -0.58%      
      qoq
    		8.31% -11.70% 36.04% -3.98% 10.59% 7.02% -15.12% 28.14% 25.61% -32.97% -38.22% 38.96% -24.80% 0.08% 12.59%       -63.81% 189.82% -8.36% -131.85% -154.37% 603.75% -65.63% 1050.98% -107.58% -385.54% -74.54% 118.26% 13.36% -8.36% -7.61% -178.13% -197.29% 15.89% 1.52% -5.16% 3.35% 5.83% -4.16%   
      net income margin %
    		-1250.95% 9174.09% -1144.46% -1073.49% -1036.46% -1816.75% -1141.73% -1339.18% -1175.94% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% NaN% NaN% NaN% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity%  
      other comprehensive income
    		                                              
      foreign currency translation adjustment
    		-103,000 3,000 46,000 -28,000 -8,000 25,000 -5,000 3,000 5,000 -7,000 5,000 -2,000 -1,000 -5,000 20,000 10,000                               
      comprehensive loss
    		-19,280,000 -17,703,000 -20,005,000 -14,767,000 -15,358,000 -13,855,000 -12,975,000 -15,277,000 -11,919,000 -9,500,000 -14,157,000 -22,928,000 -16,499,000 -21,943,000 -21,902,000 -19,461,000      -3,790,312 -10,473,847 -3,613,975 -3,943,819 12,382,067 -22,773,281 -3,236,000 -9,415,000   -3,777,000 -14,833,000 -4,904,500 -5,994,000 -6,538,000 -7,087,000          
      net loss attributable to common shareholders— basic and diluted
    		-19,177,000   -14,739,000 -15,350,000 -13,882,000 -12,970,000                                        
      weighted shares used in calculating net loss per common share — basic and diluted
    		327,543,855,000 300,167,989,000 304,003,247,000 292,067,192,000 291,996,562,000 270,995,121,000 278,171,593,000                                        
      net income per share
    		-0.06 -0.06 -0.07 -0.05 -0.05 -0.05 -0.05 -0.04 -0.05 -0.04 -0.06 -0.1 -0.07 -0.07 -0.1 -0.09 -0.09 -0.07 -0.05 -0.13 -0.04 0.02 -0.07 -0.19 -0.07 4.13 -3.55                    
      other income :
    		                                              
      net loss attributable to common shareholders — basic and diluted
    		 -12,535,000 -20,051,000                                            
      net loss attributable to series b convertible preferred shareholders — basic and diluted
    		     2                                         
      weighted shares used in calculating net loss per series b convertible preferred stock — basic and diluted
    		     54,745                                         
      unrealized gain on marketable securities
    		           -1,000                                   
      net loss — basic and diluted
    		       -15,280,000                                       
      redeemed series b convertible preferred stock
    		       4,988,000                                       
      net loss available to common shareholders— basic and diluted
    		       -10,292,000                                       
      shares used in calculating net loss per common share — basic and diluted
    		       257,353,857,000 257,232,636,000 4,104,390,000 256,492,558,000 238,311,498,000 225,523,627,000 1,844,305,000 216,591,011,000 215,862,977,000 205,693,498,000 48,399,881,250 198,790,980,000 195,572,189,000 186,298,122,000 19,471,953 141,591,218 83,537,463                       
      income before income taxes
    		             -21,939,000 -21,922,000   -14,581,000 -10,807,000                            
      income tax benefit
    		                  -52,000                            
      net loss and comprehensive loss
    		                -18,019,000 -10,946,000 -10,755,000 -25,952,000 -7,077,000                          
      revenues
    		                                              
      collaboration revenue
    		                       42,620                       
      total revenues
    		                       42,620                       
      in-process research and development
    		                      7,000,000                        
      deemed dividend related to warrant exchange
    		                       -12,546,340                       
      net loss to common stockholders
    		                 -14,581,000 -10,755,000 -25,952,000  -3,790,312 -10,473,847 -16,160,315                       
      change in fair value of derivative liabilities
    		                                              
      loss on debt conversion
    		                                              
      weighted-average common shares outstanding — basic and diluted
    		                        52,627,228                      
      weighted-average shares outstanding — basic and diluted
    		                          6,411,308                    
      revenue
    		                                              
      operating expenses:
    		                                              
      restructuring charge
    		                                              
      loss due to asset impairment
    		                                              
      other income:
    		                                              
      loss on extinguishment of lease obligations
    		                           -270,000                   
      change in fair value of warrant liability
    		                           -5,000 -1,407,000 8,077,000 17,776,000 3,501,000 -8,753,000 -809,000 -269,000 -135,000 -269,000 16,968,000 539,000        
      net loss attributable to common stockholders—basic and diluted
    		                           -3,230,000 -9,394,000   -3,697,000 -14,370,000   -5,454,000     -7,918,000      
      net loss per common share—basic and diluted
    		                           -30 -120   -130 -520 -185 -230 -250     -600      
      weighted-average shares used for eps calculation
    		                           94,599,601,000 80,484,113,000 36,398,450,000 29,737,632,000 28,740,030,000 27,670,118,000 22,669,819,000 22,552,341,000 22,183,804,000 21,914,001,000 14,256,954,000 13,297,546,000 13,270,433,000 13,269,021,000 13,231,126,000 13,238,997,000 13,215,701,000 13,201,186,000  
      restructuring
    		                            2,789,000                  
      loss on asset impairment
    		                            750,000                  
      other expense
    		                            -5,000 -17,750 -21,000 -26,000 -24,000 26,000 -52,000 -73,000 -17,000 50,000 -130,000 -66,000 -101,000      
      other comprehensive income:
    		                                              
      unrealized gain from available for sale securities
    		                                  1,000 4,000           
      comprehensive income
    		                             -1,956,250 10,785,000                
      net income attributable to common stockholders—basic
    		                             -1,914,250 10,650,000                
      net (loss) attributable to common stockholders—diluted
    		                             -5,045,250 -7,126,000                
      net income per common share—basic
    		                             -67.5 360                
      net loss per common share—diluted
    		                             -170 -240                
      other comprehensive loss:
    		                                              
      total other expense
    		                                -8,740,000 -175,250 -282,000  -251,000 -717,500 -2,667,000 -83,000 -120,000      
      unrealized loss from available for sale securities
    		                                    -6,000          
      warrant expense
    		                                     -44,000 -3,056,000        
      net loss attributable to common stockholders— basic and diluted
    		                                 -4,095,000 -5,080,000            
      total other (expense)
    		                                   -168,000           
      loss attributable to common stockholders—basic and diluted
    		                                    -5,832,000 -6,299,250 -9,234,000 -8,038,000  -5,918,750 -8,078,000 -7,633,000   
      loss per common share—basic and diluted
    		                                    -270 -475 -700 -610       
      other expense:
    		                                              
      change in fair value of warrant liability, other liability and net sales distribution payment liability
    		                                              
      loss per common share—basic and diluted:
    		                                         -447.5 -610 -580   
      loss attributable to common stockholders — basic and diluted
    		                                            -7,964,000  
      loss per common share — basic and diluted:
    		                                            -600  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 
                                                    
        assets
      		                                              
        current assets
      		                                              
        cash
      		31,855,000 18,571,000 32,565,000 27,013,000 37,800,000 58,514,000 38,696,000                                        
        prepaid expenses and other current assets
      		6,696,000 5,769,000 5,074,000 5,870,000 6,164,000 3,168,000 1,977,000 2,920,000 3,623,000 3,509,000 3,081,000 2,874,000 7,680,000 7,558,000 5,895,000 7,564,000 8,256,000 2,700,000 1,113,000 996,000 1,576,000 1,838,357 652,893 924,500 1,169,297 1,322,167 517,562 414,000 764,000 858,000 825,000 881,000 858,000 194,000 258,000 304,000 296,000 173,000 201,000 350,000 466,000 321,000 365,000 897,000 829,000 796,000 
        total current assets
      		38,551,000 24,340,000 37,639,000 32,883,000 43,964,000 61,682,000 40,673,000 18,617,000 29,998,000 42,971,000 56,558,000 73,452,000 84,401,000 98,492,000 107,497,000 122,569,000 138,027,000 102,646,000 113,450,000 121,626,000 51,356,000 25,877,682 19,758,723 22,892,661 11,362,485 15,766,219 22,818,644 3,200,000 8,140,000 16,400,000 6,017,000 9,653,000 16,365,000 8,175,000 12,877,000 18,844,000 24,670,000 32,081,000 38,195,000 16,276,000 23,363,000 31,236,000 38,088,000 46,119,000 54,010,000 58,856,000 
        property and equipment
      		13,830,000 14,392,000 14,946,000 15,445,000 15,989,000 16,554,000 17,130,000 17,474,000 17,654,000 17,290,000 14,469,000 11,720,000 7,952,000 6,053,000 4,517,000 3,153,000 1,921,000 1,164,000 1,052,000 944,000 762,000 632,967 214,100 232,354 248,997 222,464 213,229  135,000 141,000 4,352,000 5,173,000 4,448,000 2,723,000 2,814,000 3,146,000 3,503,000 3,860,000 4,263,000 4,665,000 4,815,000 5,213,000 5,513,000 5,428,000 5,422,000 4,878,000 
        restricted cash
      		318,000 316,000 314,000 312,000 309,000 307,000 305,000 302,000         151,000 151,000 151,000 151,000 151,000 151,226 151,196 151,157 151,100 151,016 150,910  137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 137,000 604,000 604,000 
        other assets
      		4,206,000 4,468,000 4,697,000 4,954,000 4,198,000 3,899,000 3,828,000 4,149,000 4,142,000 4,286,000 3,660,000 3,804,000 3,946,000 4,087,000 4,225,000 4,366,000 1,628,000 1,800,000 1,659,000 1,530,000 1,578,000 714,477 415,555 482,711 551,163 667,747 436,094   750,000                 
        total assets
      		56,905,000 43,516,000 57,596,000 53,594,000 64,460,000 82,442,000 61,936,000 40,542,000 51,794,000 64,547,000 74,687,000 88,976,000 96,299,000 108,632,000 116,239,000 130,088,000 141,727,000 105,761,000 116,312,000 124,251,000 53,847,000 27,376,352 20,539,574 23,758,883 12,313,745 16,807,446 23,618,877 3,200,000 14,838,000 17,428,000 10,881,000 15,151,000 21,325,000 11,035,000 15,828,000 22,127,000 28,310,000 36,078,000 42,795,000 21,278,000 28,515,000 36,786,000 45,301,000 53,238,000 61,580,000 65,499,000 
        liabilities and stockholders' equity
      		                                              
        current liabilities
      		                                              
        accounts payable
      		3,241,000 6,202,000 4,574,000 4,237,000 3,224,000 4,243,000 1,494,000 3,391,000 1,731,000 3,172,000 2,921,000 3,881,000 8,092,000 8,062,000 6,460,000 5,921,000 3,896,000 2,312,000 2,095,000 802,000 1,040,000 395,034 222,340 507,864 1,548,309 1,895,613 5,791,298 538,000 1,100,000 1,590,000 1,690,000 2,207,000 1,362,000 776,000 827,000 1,618,000 1,887,000 1,588,000 1,665,000 1,769,000 1,713,000 2,253,000 2,001,000 2,337,000 3,293,000 4,886,000 
        accrued expenses and other current liabilities
      		11,612,000 14,733,000 14,932,000 12,899,000 12,926,000 15,500,000 12,475,000 12,814,000 12,434,000 13,343,000 6,399,000 7,787,000 5,823,000 9,900,000    4,325,000 3,962,000 3,870,000 2,703,000                          
        operating lease obligations
      		850,000 858,000 855,000 853,000 736,000 519,000 477,000 461,000 589,000 574,000 540,000 526,000 512,000 498,000 443,000 314,000 254,000 363,000                             
        current portion of long-term debt
      		5,005,000                                              
        total current liabilities
      		20,708,000 23,043,000 20,361,000 17,989,000 16,886,000 21,588,000 15,762,000 17,972,000 16,050,000 17,089,000 11,136,000 13,460,000 15,683,000 18,460,000 14,907,000 10,338,000 7,687,000 7,000,000 6,229,000 4,840,000 4,281,000 3,613,551 4,130,787 7,041,353 3,314,998 4,543,959 35,412,756   2,873,000 8,943,000 11,657,000 8,420,000 3,805,000 2,914,000 3,827,000 3,895,000 5,171,000 7,209,000 6,721,000 5,975,000 6,359,000 6,690,000 6,687,000 7,499,000 8,251,000 
        non-current liabilities
      		                                              
        operating lease obligations, less current portion
      		3,252,000 3,494,000 3,709,000 3,945,000 3,418,000 3,313,000 3,419,000 3,546,000 3,414,000 3,567,000 3,164,000 3,308,000 3,449,000 3,587,000 3,764,000 3,892,000 1,180,000 1,231,000                             
        long term debt
      		24,189,000 27,542,000 28,400,000 28,025,000 27,669,000 27,345,000 1,571,000 1,552,000 1,533,000 2,800,000 1,495,000 1,472,000 1,058,000 2,289,000 2,265,000 1,750,000 1,731,000 1,712,000 1,693,000 1,674,000 1,702,000 1,823,043 1,944,396 2,018,926 1,580,560 1,072,123 1,058,191                    
        other non-current liabilities
      		2,951,000 1,603,000 1,593,000 583,000 573,000 564,000 554,000 545,000 536,000 527,000 497,000 455,000 309,000 244,000           3,940 9,755                     
        total non-current liabilities
      		30,392,000 32,639,000 33,702,000 32,553,000 31,660,000 31,222,000 5,544,000 5,643,000 5,483,000 6,894,000 5,156,000 5,235,000 4,816,000 6,120,000 6,029,000 5,642,000 2,911,000 2,943,000 2,973,000 3,002,000 3,077,000 2,212,360 1,987,142 2,094,503 1,701,642 1,245,076 1,299,383                    
        total liabilities
      		51,100,000 55,682,000 54,063,000 50,542,000 48,546,000 52,810,000 21,306,000 23,615,000 21,533,000 23,983,000 16,292,000 18,695,000 20,499,000 24,580,000 20,936,000 15,980,000 10,598,000 9,943,000 9,202,000 7,842,000 7,358,000 5,825,911 6,117,929 9,135,856 5,016,640 5,789,035 36,712,139 11,931,000 20,370,000 17,886,000 20,557,000 38,589,000 41,395,000 22,303,000 20,641,000 21,321,000 21,338,000 22,511,000 38,759,000 8,389,000 7,923,000 8,588,000 9,125,000 9,373,000 10,356,000 11,293,000 
        commitments and contingencies
      		                                              
        stockholders' equity
      		                                              
        preferred stock; 0.01 par value...
      		                                              
        common stock; 0.01 par value...
      		3,384,000 3,125,000 3,125,000 2,924,000 2,922,000 2,915,000 2,904,000 2,576,000 2,575,000 2,567,000 2,566,000 2,566,000 2,265,000 2,217,000 2,168,000 2,163,000 2,158,000 1,995,000 1,990,000 1,988,000 1,883,000 1,841,334 1,621,480 1,351,281                       
        treasury stock
      		-48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -48,000 -47,864 -47,864 -47,864 -47,864 -47,864                     
        additional paid-in capital
      		429,549,000 392,763,000 390,759,000 370,474,000 368,571,000 366,938,000 364,092,000 327,742,000 325,799,000 324,191,000 322,452,000 320,181,000 303,073,000 294,874,000 284,231,000 281,139,000 278,704,000 225,537,000 222,253,000 220,799,000 125,032,000 93,058,748 82,359,494 72,357,228 62,241,145 62,018,632 50,668,493 219,911,000 219,874,000 215,859,000 206,115,000 203,173,000 202,764,000 196,760,000 196,419,000 196,045,000 195,673,000 195,181,000 194,713,000 194,277,000 193,942,000 193,631,000 193,260,000 192,871,000 192,597,000 187,620,000 
        accumulated other comprehensive income
      		164,000 61,000 58,000 12,000 40,000 48,000 23,000 28,000 25,000 20,000 27,000 22,000 25,000 26,000 30,000 10,000                               
        accumulated deficit
      		-427,244,000 -408,067,000 -390,361,000 -370,310,000 -355,571,000 -340,221,000 -326,341,000 -313,371,000 -298,091,000 -286,167,000 -266,603,000 -252,441,000 -229,516,000 -213,018,000 -191,079,000 -169,157,000 -149,686,000 -131,667,000 -117,086,000 -106,331,000 -80,379,000 -73,301,777 -69,511,465 -59,037,618 -55,423,643 -51,479,824  -229,481,000 -226,245,000 -216,830,000 -216,012,000 -226,797,000 -223,020,000 -208,187,000 -201,391,000 -195,396,000 -188,854,000 -181,773,000 -190,836,000 -181,521,000 -173,483,000 -165,565,000 -157,216,000 -149,138,000 -141,505,000 -133,541,000 
        total stockholders' equity
      		5,805,000 -12,166,000 3,533,000 3,052,000 15,914,000 29,632,000 40,630,000 16,927,000 30,261,000 40,564,000 58,395,000 70,281,000 75,800,000 84,052,000 95,303,000 114,108,000 131,129,000                              
        total liabilities and stockholders' equity
      		56,905,000 43,516,000 57,596,000 53,594,000 64,460,000 82,442,000 61,936,000 40,542,000 51,794,000 64,547,000 74,687,000 88,976,000 96,299,000 108,632,000 116,239,000 130,088,000 141,727,000                              
        current portion of long term debt
      		 1,250,000    1,326,000 1,316,000 1,306,000 1,296,000  1,276,000 1,266,000 1,256,000                                  
        series b convertible preferred stock; zero shares issued and outstanding at december 31, 2025 and 2024
      		                                              
        series b convertible preferred stock; zero shares issued and outstanding at december 31, 2024 and 54,745 issued and outstanding at december 31, 2023
      		                                              
        convertible preferred stock; 0.01 par value...
      		                                              
        series b convertible preferred stock; zero shares issued and outstanding at september 30, 2024 and 54,745 shares issued and outstanding at december 31, 2023
      		                                              
        cash and cash equivalents
      		       15,697,000 26,375,000 39,462,000 53,477,000 70,578,000 68,259,000 77,563,000 101,602,000 115,005,000 129,771,000 94,958,000 107,349,000 115,642,000 44,792,000 24,039,325 19,105,830 14,968,161 3,193,188 7,444,052 15,301,082 2,786,000 7,376,000 15,542,000 5,192,000 8,772,000 15,507,000 7,081,000 10,798,000 10,562,000 16,374,000 31,908,000 37,994,000 15,926,000 22,897,000 30,915,000 37,723,000 45,222,000 53,181,000 58,060,000 
        series b; zero shares issued and outstanding at june 30, 2024 and 54,745 shares issued and outstanding at december 31, 2023
      		                                              
        series a; zero shares issued and outstanding at march 31, 2024 and december 31, 2023
      		                                              
        series b; 54,745 shares issued and outstanding at march 31, 2024 and december 31, 2023
      		        1,000                                      
        marketable securities
      		            8,462,000 13,371,000                    900,000 1,821,000 7,978,000 8,000,000          
        series a; zero shares issued and outstanding at december 31, 2023 and 2022, respectively
      		                                              
        series b; 54,745 issued and outstanding at december 31, 2023 and 2022
      		         1,000                                     
        series a; zero shares issued and outstanding at september 30, 2023 and december 31, 2022
      		                                              
        series b; 54,745 shares issued and outstanding at september 30, 2023 and december 31, 2022
      		          1,000                                    
        series a; zero shares issued and outstanding at june 30, 2023 and december 31, 2022
      		                                              
        series b; 54,745 shares issued and outstanding at june 30, 2023 and december 31, 2022
      		           1,000                                   
        series a; zero shares issued and outstanding at march 31, 2023 and december 31, 2022
      		                                              
        series b; 54,745 shares issued and outstanding at march 31, 2023 and december 31, 2022
      		            1,000                                  
        series a; zero and seven issued and outstanding at december 31, 2022 and 2021, respectively
      		                                              
        series b; 54,745 issued and outstanding at december 31, 2022 and 2021
      		             1,000                                 
        accrued expenses
      		              8,004,000 4,103,000 3,537,000     2,930,395 2,333,733 2,084,915 1,383,658 2,270,045 1,301,304 253,000 99,000 1,000,000 1,973,000 1,672,000 1,738,000 2,705,000 1,518,000 1,394,000 995,000 2,097,000 1,484,000 1,274,000 981,000 1,444,000 2,449,000 2,093,000 1,896,000 1,683,000 
        series a; zero and seven shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively
      		                                              
        series b; 54,745 shares issued and outstanding at september 30, 2022 and december 31, 2021
      		              1,000                                
        series a; zero and seven shares issued and outstanding at june 30, 2022 and december 31, 2021, respectively
      		                                              
        series b; 54,745 shares issued and outstanding at june 30, 2022 and december 31, 2021
      		               1,000                               
        series a; seven issued and outstanding at march 31, 2022 and december 31, 2021
      		                                              
        series b; 54,745 issued and outstanding at march 31, 2022 and december 31, 2021
      		                1,000                              
        advance for covaxin supply
      		                 4,988,000 4,988,000 4,988,000 4,988,000                          
        liabilities and stockholders’ equity
      		                                              
        short-term debt
      		                    374,000 234,119 1,210,645 4,068,176                       
        stockholders’ equity
      		                                              
        series a; seven issued and outstanding at december 31, 2021 and 2020
      		                                              
        series b; 54,745 and zero issued and outstanding at december 31, 2021 and 2020, respectively
      		                 1,000                             
        total stockholders’ equity
      		                 95,818,000 107,110,000 116,409,000 46,489,000 21,550,441 14,421,645 14,623,027 7,297,105 11,018,411    -458,000  -23,438,000 -20,070,000 -11,268,000 -4,813,000 806,000 6,972,000 13,567,000 4,036,000 12,889,000 20,592,000 28,198,000 36,176,000 43,865,000 51,224,000 54,206,000 
        total liabilities and stockholders’ equity
      		                 105,761,000 116,312,000 124,251,000 53,847,000 27,376,352 20,539,574 23,758,883 12,313,745 16,807,446    17,428,000  15,151,000 21,325,000 11,035,000 15,828,000 22,127,000 28,310,000 36,078,000 42,795,000 21,278,000 28,515,000 36,786,000 45,301,000 53,238,000 61,580,000  
        operating lease obligation
      		                  172,000 168,000 164,000 44,248 164,808 175,538 176,616 172,310 151,530                    
        operating lease obligation, less current portion
      		                  1,280,000 1,328,000 1,375,000 389,317 42,746 75,577 117,142 163,198 223,853                    
        series a; seven issued and outstanding at september 30, 2021 and december 31, 2020
      		                                              
        series b; 54,745 and zero issued and outstanding at september 30, 2021 and december 31, 2020, respectively
      		                  1,000                            
        series a; seven issued and outstanding at june 30, 2021 and december 31, 2020
      		                                              
        series b; 54,745 and zero issued and outstanding at june 30, 2021 and december 31, 2020, respectively
      		                   1,000                           
        series a; seven issued and outstanding at march 31, 2021 and december 31, 2020
      		                                              
        series b; 54,745 and zero issued and outstanding at march 31, 2021 and december 31, 2020, respectively
      		                    1,000                          
        asset held for sale
      		                       7,000,000 7,000,000 7,000,000 7,000,000                    
        other current liabilities
      		                     9,755 199,261 204,860 206,415 205,991                     
        convertible preferred stock, 0.01 par value...
      		                                              
        common stock, 0.01 par value...
      		                        527,467 527,467  839,000 839,000 513,000 221,000 186,000 186,000 159,000 159,000 159,000 159,000 159,000 159,000 133,000 133,000 132,000 132,000 132,000 132,000 127,000 
        derivative liabilities
      		                                              
        financing lease obligation
      		                          19,838                    
        short-term warrant liability
      		                          27,964,986                    
        deferred grant proceeds
      		                          183,800                    
        deferred rent
      		                             351,000                 
        financing lease obligation, less current portion
      		                          17,339                    
        stockholders’ deficit
      		                                              
        common stock
      		                          100,136                    
        total stockholders’ deficit
      		                           -8,731,000 -5,532,000  -9,676,000                
        total liabilities and stockholders’ deficit
      		                          23,618,877 3,200,000 14,838,000  10,881,000                
        current assets:
      		                                              
        other assets, long-term
      		                            6,426,000  375,000 188,000 375,000              
        liabilities and stockholders’ deficit
      		                                              
        current liabilities:
      		                                              
        current portion of deferred rent
      		                             45,000 42,000 40,000 37,000 35,000 60,000 86,000 110,000 136,000 133,000 131,000 128,000 126,000 225,000 223,000 224,000 219,000 
        current portion of deferred lease incentive
      		                             238,000 238,000 238,000 238,000 111,000 185,000 259,000 333,000 407,000 407,000 407,000 407,000 407,000 379,000 407,000 514,000 407,000 
        total current liabilities:
      		                           791,000 2,317,000                  
        accrued expenses due to intrexon corporation
      		                           1,125,000 1,125,000 1,125,000 3,040,000 3,040,000 3,040,000 3,040,000 3,040,000 3,040,000 3,040,000  2,802,000 2,288,000 1,903,000      
        deferred revenue
      		                           10,000,000 10,000,000 10,000,000                 
        deferred rent, net of current portion
      		                              334,000 317,000 299,000              
        deferred lease incentive, net of current portion
      		                              1,085,000 1,144,000 1,204,000              
        warrant liability
      		                           15,000 10,000 2,512,000 2,155,000 19,931,000 23,432,000 14,679,000 13,871,000 13,601,000 13,467,000 13,197,000 30,165,000        
        convertible preferred stock and stockholders’ deficit:
      		                                              
        accrued lease liability – current portion
      		                            1,118,000                  
        accrued lease liability – long-term
      		                            6,918,000                  
        current portion of equipment loan
      		                                45,000 178,000 324,000 470,000 570,000 583,000 583,000 583,000 583,000 583,000 583,000 583,000 538,000 405,000 
        deferred lease incentive
      		                             1,025,000                 
        convertible preferred stock and stockholders’ equity
      		                                              
        current portion of deferred revenue
      		                              5,000,000 7,500,000 5,000,000              
        deferred revenue, net of current portion
      		                              5,000,000 2,500,000 5,000,000              
        accounts payable due to intrexon corporation
      		                                     360,000 135,000 269,000 260,000      
        deferred rent, long-term
      		                                 280,000 289,000 298,000 308,000 315,000 349,000 384,000 418,000 451,000 381,000 413,000 445,000 379,000 
        deferred lease incentive, long-term
      		                                 499,000 527,000 555,000 583,000 610,000 712,000 814,000 915,000 1,017,000 1,147,000 1,220,000 1,213,000 1,318,000 
        equipment loan, long-term
      		                                    45,000 178,000 324,000 470,000 615,000 761,000 907,000 1,053,000 1,199,000 1,345,000 
        convertible preferred stock and stockholders’ equity:
      		                                              
        accumulated other comprehensive loss
      		                                   -2,000 -6,000          
        intangible asset
      		                                      200,000 200,000 200,000 200,000 510,000 510,000 510,000 510,000 
        stockholders’ equity:
      		                                              
        preferred stock, 0.01 par value...
      		                                              
        noncurrent deferred tax assets
      		                                          1,053,000 1,044,000 1,034,000 651,000 
        accrued expenses due to intrexon
      		                                         1,546,000     
        noncurrent deferred tax liabilities
      		                                              
        deferred tax liabilities
      		                                          1,053,000 1,044,000 1,034,000 651,000 
        initial public offering costs
      		                                              
        liabilities, convertible redeemable preferred stock and stockholders’ equity
      		                                              
        net sales distribution payment liability
      		                                              
        other liability
      		                                              
        convertible redeemable preferred stock
      		                                              
        series a convertible redeemable preferred stock, 0.01 par value...
      		                                              
        series a-1 convertible redeemable preferred stock, 0.01 par value...
      		                                              
        total liabilities, convertible redeemable preferred stock and stockholders’ equity
      		                                             65,499,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
                                                     
          cash flows from operating activities
        		                                             
          net loss
        		-19,177,000 -17,706,000 -20,051,000 -14,739,000 -15,350,000 -13,880,000 -12,970,000 -15,280,000 -11,924,000 -9,493,000 -14,162,000 -22,925,000 -16,498,000 -21,939,000 -21,922,000 -19,471,000 -18,019,000 -14,581,000 -10,755,000 -25,952,000 -7,077,000 -3,790,312 -10,473,847 -3,613,975 -3,943,819 12,382,067 -19,973,697 -3,236,000 -9,415,000 -818,000 10,785,000 -3,777,000 -14,833,000 -6,796,000 -5,995,000 -6,542,000 -7,081,000 9,063,000 -9,315,000 -8,038,000 -7,918,000 -8,349,000 -8,078,000 -7,633,000 -7,964,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                             
          depreciation and amortization expense
        		590,000 -397,000 950,000 927,000 909,000 598,000 613,000 578,000 179,000 179,000 177,000 174,000 174,000 173,000 141,000 90,000 76,000                             
          amortization of debt issuance cost
        		377,000                                             
          non-cash interest expense
        		25,000 25,000 25,000 25,000 25,000 29,000 30,000 28,000 29,000 29,000 33,000 30,000 24,000 25,000 20,000 19,000 19,000 19,000 19,000 20,000 20,000 166,162 291,909 248,143 14,749 14,975                    
          non-cash lease expense
        		323,000 326,000 324,000 323,000 297,000 222,000 405,000 89,000 140,000 137,000 136,000 134,000 131,000 130,000 129,000 155,000 179,000 160,000 66,000 66,000 68,000 46,477 47,555 47,696 47,696                     
          non-cash expense from collaborative arrangements
        		-698,000 222,000 -918,000 -1,098,000 -668,000  -4,151,000 832,000 913,000                                     
          stock-based compensation expense
        		3,398,000 2,002,000 1,975,000 1,845,000 1,885,000 1,876,000 1,892,000 1,898,000 1,761,000 1,722,000 2,174,000 2,632,000 2,689,000 2,668,000 2,495,000 2,079,000 3,299,000 2,683,000 1,347,000 2,095,000 833,000 162,305 126,290 149,209 222,513 164,075                    
          other
        		10,000 1,010,000 9,000 10,000 10,000 9,000 9,000 10,000 9,000 -333,000 -60,000 87,000 352,000 1,152,000                                
          changes in assets and liabilities:
        		                                             
          prepaid expenses and other current assets
        		-927,000 -694,000 795,000 294,000 -3,002,000 -1,340,000 1,134,000 684,000 -117,000 -428,000 -440,000 632,000 -60,000               292,000 94,000 -33,000 56,000 -23,000 -664,000 64,000 46,000 -9,000 -122,000 28,000 149,000 116,000 -145,000 44,000 532,000 -68,000 -33,000 
          accounts payable and accrued expenses
        		-5,398,000 1,206,000 3,289,000 2,084,000 -3,268,000 2,089,000 2,161,000 1,333,000 -1,446,000 -2,284,000 -1,434,000 -3,841,000 -4,784,000 2,895,000 3,748,000 2,713,000 131,000 573,000 1,442,000 1,078,000 405,000 592,245 86,795 5,966 -1,225,853 -3,673,849                    
          lease obligations
        		-317,000   -401,000 -195,000 -216,000 -395,000 -83,000 -139,000 -135,000 -130,000 -127,000 -125,000 -122,000 4,000 -89,000 -176,000 -175,000 -61,000 -61,000 -69,000 -51,655 -47,916 -48,056 -47,862                     
          net cash from operating activities
        		-21,794,000 -13,961,000 -12,916,000 -10,730,000 -19,357,000 -10,364,000 -11,272,000 -9,911,000 -10,595,000 -11,302,000 -13,706,000 -18,806,000 -18,240,000 -16,914,000 -14,302,000 -13,797,000 -15,066,000 -12,804,000 -8,053,000 -21,801,000 -5,283,000 -4,282,277 -2,653,847 -3,086,183 -4,686,423   -3,057,000 -8,492,000 -6,938,000 -6,912,000 -5,213,000 3,286,000 -4,319,000 -5,727,000 -5,629,000 -7,345,000 -5,893,000 -5,459,000 -6,543,000 -7,841,000 -6,997,000 -6,882,000 -7,466,000 -8,689,000 
          capital expenditures
        		-6,000 -35,000 -91,000 -43,000 -16,000 -13,000 -507,000 -513,000 -2,352,000 -2,722,000 -3,365,000 -2,777,000 -1,612,000 -2,024,000 0 -1,366,000 -223,000 -192,000 -223,000 -263,000 -261,000 -251,337 -21,030 18,195 -52,653   0  -73,000 -7,000 -1,530,000 -350,000 -144,000 -57,000 -38,000 -37,000 -3,000 -3,000 -282,000 -32,000 -131,000 -498,000 -405,000 -915,000 
          free cash flows
        		-21,800,000 -13,996,000 -13,007,000 -10,773,000 -19,373,000 -10,377,000 -11,779,000 -10,424,000 -12,947,000 -14,024,000 -17,071,000 -21,583,000 -19,852,000 -18,938,000 -14,302,000 -15,163,000 -15,289,000 -12,996,000 -8,276,000 -22,064,000 -5,544,000 -4,533,614 -2,674,877 -3,067,988 -4,739,076   -3,057,000  -7,011,000 -6,919,000 -6,743,000 2,936,000 -4,463,000 -5,784,000 -5,667,000 -7,382,000 -5,896,000 -5,462,000 -6,825,000 -7,873,000 -7,128,000 -7,380,000 -7,871,000 -9,604,000 
          cash flows from investing activities
        		                                             
          purchases of property and equipment
        		-6,000 -35,000 -91,000 -43,000 -16,000 -13,000 -507,000 -513,000 -2,352,000 -2,722,000 -3,365,000 -2,777,000 -1,612,000 -2,024,000                -73,000 794,000 -1,479,000 -1,255,000 -144,000 -57,000 -38,000 -37,000 -3,000 -3,000 -282,000 -32,000 -131,000 -498,000 -405,000 -915,000 
          payment of long term deposits
        		    -86,000                                         
          net cash from investing activities
        		-6,000 -35,000 -86,000 -88,000 -102,000 -13,000 -507,000 -513,000 -2,352,000 -2,722,000 -3,365,000 5,723,000 3,441,000 -15,295,000 -83,000 -1,366,000 -223,000 -192,000 -350,000 -1,013,000 -261,000 -251,337 -21,030 18,195 -52,653     -73,000 794,000 -1,479,000 -355,000 747,000 6,104,000 -38,000 -8,043,000 -3,000 -3,000 -282,000 -32,000 -131,000 -498,000 -405,000 -915,000 
          cash flows from financing activities
        		                                             
          proceeds from issuance of common stock
        		22,500,000     981,000 37,675,000 45,000 -145,000 16,000 98,000 14,959,000 5,731,000 8,369,000 612,000 409,000 50,177,000 605,000 110,000 100,371,000 28,125,000 11,129,648 10,532,138                       
          proceeds from issuance of common stock upon exercise of warrants
        		15,000,000                                             
          proceeds from exercise of equity awards
        		88,000                                             
          payment of equity issuance costs
        		-1,779,000     0    0 -133,000 -49,000 -173,000 -251,000 -98,000 -125,000 -75,000 0 0 -6,703,000 -1,822,000 -393,816 -491,038                       
          payment of warrant issuance costs
        		-825,000                                             
          payment of eb-5 loan
        		 0 0 0 -1,000,000                                         
          net cash from financing activities
        		34,984,000 2,000 18,510,000 61,000 -1,245,000 30,172,000 34,786,000 45,000 -145,000 16,000 -35,000 15,404,000 5,496,000 8,175,000 962,000 236,000 50,102,000 605,000 110,000 93,664,000 26,297,000 9,467,139 6,812,585 14,843,018 488,296 907,587 25,612,868 -1,780,000 326,000 17,361,000 2,538,000 -43,000 5,495,000 -145,000 -141,000 -145,000 -146,000 -190,000 27,530,000 -146,000 -145,000 -147,000 -119,000 -88,000 4,725,000 
          effect of changes in exchange rate on cash and restricted cash
        		102,000 3,000 46,000 -28,000 -8,000 25,000                                        
          net increase in cash and restricted cash
        		13,286,000                                             
          cash and restricted cash at beginning of period
        		18,887,000 0 0 0 58,821,000 0                                        
          cash and restricted cash at end of period
        		32,173,000 -13,992,000 5,554,000 -10,784,000 38,109,000 19,820,000                                        
          supplemental disclosure of non-cash investing and financing transactions:
        		                                             
          right-of-use assets related to operating leases
        		                                             
          amortization of debt issuance costs
        		                                             
          payment of security deposits
        		 0 5,000                                           
          proceeds from issuance of debt
        		         0 0   0        0 0 421,415 500,000                     
          payments of debt issuance costs
        		                     0 0                       
          other non-current liabilities
        		                                             
          issuance of common stock and warrants
        		                                             
          net decrease in cash and restricted cash
        		  5,554,000                                           
          series b convertible preferred stock reacquisition
        		                                             
          right-of-use asset related to operating leases
        		  -37,000    0             0 926,000     107,263                    
          payments from issuance of common stock
        		   61,000 -245,000                                         
          net (decrease) in cash and restricted cash
        		    -20,712,000 19,820,000                                        
          right-of-use assets
        		    428,000                                         
          amortization on marketable securities
        		         0 0 -39,000 -143,000                                 
          non-cash income from collaborative arrangements
        		                                             
          impairment of advance for covaxin supply
        		         0 0                                   
          loss on disposal of fixed assets related to covaxin
        		         0 0                                   
          purchases of marketable securities
        		         0 0 0 -3,947,000                     0 2,000 0 -8,006,000         
          proceeds from the maturities of marketable securities
        		          0 8,500,000 9,000,000                                 
          repayment of note receivable
        		             0                                
          payment of debt issuance costs
        		          0 -6,000 -62,000            -5,740                     
          effect of changes in exchange rate on cash, cash equivalents, and restricted cash
        		            -1,000 -5,000 20,000                               
          net (decrease) in cash, cash equivalents, and restricted cash
        		                                             
          cash, cash equivalents, and restricted cash at beginning of period
        		         0 0 0 77,563,000 0 0 0 95,109,000 0 0 0 24,190,000                         
          cash, cash equivalents, and restricted cash at end of period
        		            68,259,000 -24,039,000 -13,403,000 -14,917,000 129,922,000 -12,391,000 -8,293,000 70,850,000 44,943,000                         
          equity issuance costs
        		               -2,000 71,000    108,000 -20,971    0                    
          series b convertible preferred stock redemption
        		                                             
          effect of changes in exchange rate on cash and cash equivalents
        		        5,000 -7,000 5,000                                   
          net (decrease) in cash and cash equivalents
        		        -13,087,000                                     
          cash and cash equivalents at beginning of period
        		        39,462,000                                     
          cash and cash equivalents at end of period
        		        26,375,000 -14,015,000 -17,101,000                                   
          proceeds from maturities of marketable securities
        		                             0 0 0 900,000 891,000            
          net increase in cash and cash equivalents
        		          -17,101,000                       -3,717,000    -6,086,000        
          debt issuance costs
        		                                             
          net increase in cash, cash equivalents, and restricted cash
        		            -9,304,000 -24,039,000 -13,403,000 -14,917,000 34,813,000 -12,391,000 -8,293,000 70,850,000 20,753,000                         
          income tax benefit
        		                 0                            
          gain on forgiveness of paycheck protection program note
        		                                             
          impairment on note receivable
        		                 0 3,000                           
          other assets
        		                 0 0       -261,946                    
          asset acquisition
        		                                             
          issuance of note receivable
        		                 0 0                           
          financing lease principal payments
        		                 0 0 -4,000 -6,000 -5,964 -5,964 -5,964 -5,964                     
          prepaid expenses and other assets
        		              1,756,000 707,000 -575,000  -120,000 472,000 493,000  295,562 270,966 227,870                     
          tax payments for net share settlement of restricted stock units
        		              -9,000                               
          purchase of property and equipment
        		               -1,366,000 -223,000 -192,000 -223,000 -263,000 -261,000 -251,337 -21,030 18,195 -52,653                     
          series b convertible preferred stock issuance
        		                   0 4,988,000                         
          exercise of warrants
        		                                             
          forgiveness of paycheck protection program note
        		                                             
          in-process research and development expense
        		                     0                        
          change in fair value of derivative liability
        		                         -16,709,246                    
          loss on debt conversion
        		                                             
          gain on forgiveness of ppp note
        		                 0 0                           
          other non-cash
        		                     -183,800 0                       
          payments for asset acquisitions
        		                                             
          purchases of treasury stock
        		                                             
          proceeds from pre-merger financing
        		                                             
          repayments of debt
        		                     -1,262,729 -3,222,551                       
          depreciation expense
        		                  58,000 49,000 44,000 44,545 19,805 19,477 18,283 25,982                    
          forgiveness of ppp note
        		                                             
          issuance of warrant exchange promissory notes
        		                     0 0                       
          obligation settled with common stock
        		                     0 0                       
          supplemental disclosure of non-cash transactions:
        		                                             
          payment of reverse asset acquisition costs
        		                                             
          net increase in cash, cash equivalents and restricted cash
        		                     4,933,525 4,137,708   -7,856,924                    
          cash, cash equivalents and restricted cash at beginning of period
        		                     0 0 0 7,595,068 0                    
          cash, cash equivalents and restricted cash at end of period
        		                     4,933,525 4,137,708 11,775,030 3,344,288 -7,856,924                    
          conversion of convertible notes
        		                         -12,719,893                    
          reverse asset acquisition costs
        		                         -458,636                    
          effect of changes in exchange rate on cash
        		                                             
          deferred transaction costs
        		                                             
          deferred equity issuance costs
        		                                             
          net decrease in cash, cash equivalents and restricted cash
        		                        -4,250,780                     
          deferred rent
        		                                             
          purchase of property, plant and equipment
        		                                             
          payment of asset acquisition costs
        		                                             
          proceeds from sale of common stock for pre-merger financing
        		                                             
          proceeds from stock subscription
        		                         168                    
          issuance of common stock for warrant exercises
        		                                             
          payments on financing leases
        		                                             
          purchase of fixed assets by entering into capital lease
        		                                             
          proceeds from issuance of convertible debt
        		                                             
          repayment of convertible debt
        		                                             
          conversion of convertible promissory note
        		                                             
          cash flows from operating activities:
        		                                             
          depreciation and amortization
        		                                             
          loss on asset impairment
        		                           0 750,000                 
          loss on extinguishment of lease obligations
        		                                             
          loss on sale of fixed assets
        		                                             
          deferred rent and lease incentive
        		                             -40,000 -40,000 -39,000 853,000 -136,000 -137,000 -136,000 -134,000 -133,000 -135,000 -132,000 -133,000 -131,000 -131,000 -133,000 73,000 
          stock-based compensation
        		                           37,000 107,000 376,000 439,000 407,000 403,000 340,000 369,000 372,000 492,000 468,000 433,000 336,000 311,000 374,000 362,000 257,000 235,000 
          change in fair value of warrant liability
        		                           5,000 1,407,000                 
          changes in operating assets and liabilities:
        		                                             
          other assets and accrued lease obligations
        		                           -153,000 -49,000                 
          accounts payable
        		                           -560,000 -491,000 -172,000 -570,000 845,000 586,000 -88,000 -791,000 -269,000 299,000 -77,000 -103,000 56,000 -311,000 252,000 -336,000 -956,000 -1,593,000 
          accrued expenses
        		                           154,000 -901,000 -973,000 339,000 538,000 -1,609,000 1,102,000 125,000 400,000 -1,103,000 613,000 210,000 293,000 -463,000 -998,000 356,000 197,000 213,000 
          deferred revenue
        		                             0 0 0 10,000,000             
          cash flows from investing activities:
        		                                             
          proceeds from sale of fixed assets
        		                                             
          cash flows from financing activities:
        		                                             
          payment to extinguish lease obligations
        		                                             
          repayments on equipment term loan
        		                             0 0 -45,000 -133,000 -146,000 -146,000 -145,000 -146,000 -146,000 -146,000 -145,000 -146,000     
          net proceeds from issuance of common stock
        		                              2,432,000 0 5,732,000             
          expenses incurred for at-the-market sales agreement of common stock
        		                               0 -106,000             
          proceeds from exercise of warrants
        		                           0 326,000  0               
          proceeds from exercise of stock options
        		                              0 0 2,000 1,000    0   1,000     
          net increase in cash and cash equivalents and restricted cash
        		                           -4,727,000 -8,166,000   -6,735,000 8,426,000             
          cash and cash equivalents and restricted cash—beginning of period
        		                           0 15,679,000  0 0 7,218,000             
          cash and cash equivalents and restricted cash—end of period
        		                           -4,727,000 7,513,000  -3,580,000 -6,735,000 15,644,000             
          reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:
        		                                             
          cash and cash equivalents
        		                           -4,590,000 7,376,000                 
          restricted cash
        		                            137,000                 
          total cash, cash equivalents, and restricted cash at the end of period
        		                           -4,727,000 7,513,000                 
          supplemental cash flow disclosures from investing and financing activities:
        		                                             
          purchases of property and equipment in accounts payable and accrued expenses
        		                              -801,000 -51,000 905,000             
          depreciation
        		                            6,000 86,000 42,000 150,000 172,000 356,000 389,000 395,000 394,000 406,000 405,000 432,000 430,000 432,000 414,000 397,000 371,000 
          right-of-use assets and lease liability recorded upon adoption of asc 842
        		                            6,635,000                 
          public offering costs in accounts payable
        		                                106,000             
          amortization of discount of investments
        		                                 30,000 -2,000 25,000 1,000         
          warrant expense
        		                                         -3,000 -1,000   
          change in warrant liability
        		                                             
          loss due to asset impairment
        		                                             
          gain on extinguishment of liability due to intrexon corporation
        		                                             
          other long term assets
        		                                             
          accounts payable due to intrexon corporation
        		                                 0 0 0 -360,000 225,000 -134,000 9,000 31,000     
          accrued expenses due to intrexon corporation
        		                                     238,000 514,000 385,000 357,000     
          proceeds from issuance of common stock, net of issuance costs
        		                                             
          proceeds from exercise of stock options and warrants
        		                                             
          cash and cash equivalents and restricted cash —beginning of period
        		                                             
          cash and cash equivalents and restricted cash —end of period
        		                                             
          supplemental disclosure of non-cash items:
        		                                             
          purchases of property and equipment in accounts payable
        		                                             
          supplemental disclosure of cash flow information:
        		                                             
          cash paid for taxes
        		                                             
          cash paid for interest
        		                                             
          change in fair value of warrant
        		                              -17,776,000 -3,501,000 8,753,000 809,000 269,000 135,000 269,000 -16,968,000        
          other assets, long-term
        		                              -187,000 187,000 -375,000             
          net decrease in cash and cash equivalents and restricted cash
        		                                             
          public offering costs in accounts payable and accrued expenses
        		                                             
          impairment of intangible asset
        		                                             
          warrant expense in connection with private placement
        		                                             
          proceeds from issuance of common stock, preferred stock, and warrants in connection with private placement, net of issuance costs
        		                                             
          cash and cash equivalents—beginning of period
        		                                 0 0 0 31,908,000 0 0 0 30,915,000 467,000 0   
          cash and cash equivalents—end of period
        		                                 -3,717,000 236,000 -5,812,000 16,374,000 -6,086,000 22,068,000 -6,971,000 22,897,000 -6,808,000 -7,499,000   
          fair market value of private placement warrants at issuance
        		                                     0        
          proceeds from issuance of common stock, preferred stock and warrants, net of issuance costs
        		                                             
          net decrease in cash and cash equivalents
        		                                   -5,812,000 -15,534,000   -6,971,000 -8,018,000  -7,499,000   
          proceeds from overallotment, net of issuance costs of 377
        		                                            4,738,000 
          other non-current assets
        		                                          0   
          non-cash consulting expense
        		                                            9,000 
          non-cash up front fee for note payable to intrexon, including interest
        		                                             
          change in fair value of liabilities
        		                                             
          amortization of deferred financing costs
        		                                             
          accrued expenses due to intrexon
        		                                             
          proceeds from ipo, net of underwriters’ fee of 4,550
        		                                             
          proceeds from overallotment, net of issuance costs
        		                                         0 0   
          proceeds from bridge financing
        		                                             
          borrowings under equipment term loan
        		                                             
          payment on equipment term loan
        		                                         -146,000 -146,000 -101,000 -13,000 
          issuance of series a-1 preferred stock, net of issuance costs of 73
        		                                             
          costs associated with initial public offering
        		                                             
          proceeds from the exercise of common stock options
        		                                         -1,000 27,000   
          supplemental disclosure of noncash investing and financing activities:
        		                                             
          conversion of preferred stock into common stock upon closing of ipo
        		                                             
          conversion of convertible notes payable and accrued interest into common stock upon closing of ipo
        		                                             
          conversion of warrants, net settled, into common stock upon closing of ipo
        		                                             
          settlement of other liability into common stock upon closing of ipo
        		                                             
          ipo closing costs included in accounts payable and accrued expenses
        		                                             
          warrant issued in connection with an equipment term loan
        		                                             
          issuance of a note payable to intrexon as consideration for license rights
        		                                             
          extinguishment of net sales distribution payment liability redemption feature
        		                                             
          adjustment to fair value of series a-1 preferred stock related to the third closing
        		                                             
          non-cash consideration for licensed technology
        		                                             
          issuance of series a-1 preferred stock, net of cash issuance costs of 73
        		                                             
          net change in cash and cash equivalents
        		                                            -4,879,000 
          cash and cash equivalents — beginning of period
        		                                            58,060,000 
          cash and cash equivalents — end of period
        		                                            53,181,000 
          impairment of goodwill and intangible asset
        		                                             
          loss on sale of property and equipment
        		                                             
          proceeds from sale of property and equipment
        		                                             
          supplemental disclosure of noncash investing and financing activities
        		                                             
          accretion of dividends and redemption value on convertible preferred stock
        		                                             
          extinguishment of series a preferred stock